Post-marketing surveillance reports also reported an increased risk of acute cholecystitis due to GLP1-RA treatment.[114] Animal model studies have suggested that GLP1-RAs may cause pancreatitis and exocrine dysplasia [115], however, in large randomized controlled trials, GLP1-RAs did not increase the risk of pancreatitis or pancreatic cancer. This evidence concerns the gene GLP1R and pancreatitis.